Stock Scorecard
Stock Summary for Protalix BioTherapeutics Inc (PLX) - $2.50 as of 10/8/2025 4:31:16 PM EST
Total Score
9 out of 30
Safety Score
32 out of 100
Currently on the following lists
None
Tim's Recommendation
Avoid
Growth List Algorithm Criteria for PLX
| Positive Quarterly and Annual earnings growth | |
| P/E ratio less than Industry P/E Ratio | |
| P/E ratio less than Sector P/E Ratio | |
| P/E ratio that is half the Annual earnings growth rate (or less) | |
| Positive net cash position the past year and most recent quarter | |
| Equity to debt ratio greater than 0.75 for past year and most recent quarter | |
| Positive net income past year and 12 trailing months | |
| Free cash flow ratio greater than 0 and less than 10 |
Small Cap List Algorithm Criteria for PLX
| Revenue growing by at least 20% average per year over the last 5 years | |
| Market Capitalization under 2 billion | |
| Price to Sales (P/S) ratio 12 trailing months less than Industry P/S ratio twelve trailing months | |
| Price to Sales (P/S) ratio 12 trailing months less than Sector P/S ratio twelve trailing months | |
| Net Income past year > Net Income prior year OR Net Income 12 trailing months > Net Income prior year OR Net Income 12 trailing months > Net Income past year |
Dividend List Algorithm Criteria for PLX
| Declared an ex-dividend date | |
| Forward annual dividend rate greater than 2 | |
| Positive net cash position the past year and most recent quarter | |
| Equity to debt ratio greater than 0.75 for past year and most recent quarter | |
| Current ratio most recent quarter greater than 2 | |
| Cash Flow per Share greater than Trailing Dividend Rate |
Bonus Criteria for PLX
| P/E ratio less than five-year Average P/E ratio | |
| Last Price to 52 Week Low Ratio Less Than 1 | |
| Total Cash Per Share > Last Day Price | |
| P/S Ratio < 1 | |
| P/B Ratio < 1 |
Safety Rating Criteria for PLX (32 out of 100)
| Stock Price Rating (Max of 10) | 3 |
| Historical Stock Price Rating (Max of 10) | 1 |
| Stock Price Trend (Max of 10) | 10 |
| Book Value (Max of 10) | 1 |
| Book Value to Price (Max of 10) | 0 |
| Analyst Buy Ratings (Max of 5) | 0 |
| Analyst Strong Buy Ratings (Max of 5) | 0 |
| Dividend Yield Percentage (Max of 10) | 0 |
| Operating Margin (Max of 10) | 2 |
| Trading Volume (Max of 10) | 9 |
| Price to Earnings (Max of 10) | 6 |
| Geopolitical Risk Adjustment (Always 0 for USA or a Negative Number for Non-USA) | 0 |
Financial Details for PLX
Company Overview |
|
|---|---|
| Ticker | PLX |
| Company Name | Protalix BioTherapeutics Inc |
| Country | USA |
| Description | Protalix Biotherapeutics Inc. is a biopharmaceutical company specializing in the development and commercialization of recombinant therapeutic proteins using its proprietary ProCellEx plant cell-based protein expression system. Headquartered in Karmiel, Israel, Protalix's innovative approach allows for the production of complex proteins that treat various medical conditions, with a strategic focus on markets in Israel, Brazil, and Latin America. The company's commitment to advancing biotherapeutic solutions positions it as a key player in the biotech industry, catering to unmet medical needs globally. |
| Sector Name | HEALTHCARE |
| Industry Name | BIOTECHNOLOGY |
| Most Recent Quarter | 6/30/2025 |
| Next Earnings Date | 11/17/2025 |
Stock Price History |
|
| Last Day Price | 2.50 |
| Price 4 Years Ago | 0.83 |
| Last Day Price Updated | 10/8/2025 4:31:16 PM EST |
| Last Day Volume | 1,690,333 |
| Average Daily Volume | 789,993 |
| 52-Week High | 3.10 |
| 52-Week Low | 0.99 |
| Last Price to 52 Week Low | 152.53% |
Valuation Measures |
|
| Trailing PE | 28.89 |
| Industry PE | 22.22 |
| Sector PE | 41.70 |
| 5-Year Average PE | 13.54 |
| Free Cash Flow Ratio | 11.36 |
| Industry Free Cash Flow Ratio | 14.45 |
| Sector Free Cash Flow Ratio | 30.25 |
| Current Ratio Most Recent Quarter | 2.72 |
| Total Cash Per Share | 0.22 |
| Book Value Per Share Most Recent Quarter | 0.63 |
| Price to Book Ratio | 3.74 |
| Industry Price to Book Ratio | 29.58 |
| Sector Price to Book Ratio | 32.02 |
| Price to Sales Ratio Twelve Trailing Months | 3.35 |
| Industry Price to Sales Ratio Twelve Trailing Months | 44.16 |
| Sector Price to Sales Ratio Twelve Trailing Months | 20.22 |
| Analyst Buy Ratings | N/A |
| Analyst Strong Buy Ratings | N/A |
Share Statistics |
|
| Total Shares Outstanding | 79,732,000 |
| Market Capitalization | 199,330,000 |
| Institutional Ownership | 15.15% |
Dividends |
|
| Ex-Dividend Date | N/A |
| Previous Dividend Amount | 0.0000 |
| Current Dividend Amount | 0.0000 |
| Total Years Dividend Increasing | N/A |
| Trailing Annual Dividend Rate | 0.00 |
| Trailing Annual Dividend Yield | 12.10% |
| Forward Annual Dividend Rate | 0.00 |
| Forward Annual Dividend Yield | 0.00% |
| 5-Year Dividend Payments Count | 0 |
| 3-Year Average Dividend Yield | 0.00% |
| 5-Year Average Dividend Yield | 0.00% |
| 1-Year Dividend Growth Rate Percentage | 0.00% |
| 3-Year Dividend Growth Rate Percentage | 0.00% |
| 5-Year Dividend Growth Rate Percentage | 0.00% |
| All-Time Dividend Growth Rate Percentage | 0.00% |
| Dividend Payout Ratio | N/A |
Income Statement |
|
| Quarterly Earnings Growth YOY | -39.20% |
| Annual Earnings Growth | -64.73% |
| Reported EPS 12 Trailing Months | 0.09 |
| Reported EPS Past Year | -0.09 |
| Reported EPS Prior Year | 0.03 |
| Net Income Twelve Trailing Months | 6,275,000 |
| Net Income Past Year | 2,932,000 |
| Net Income Prior Year | 8,312,000 |
| Quarterly Revenue Growth YOY | 16.20% |
| 5-Year Revenue Growth | -0.48% |
| Operating Margin Twelve Trailing Months | 7.49% |
Balance Sheet |
|
| Total Cash Most Recent Quarter | 17,895,000 |
| Total Cash Past Year | 19,760,000 |
| Total Cash Prior Year | 23,634,000 |
| Net Cash Position Most Recent Quarter | -2,525,000 |
| Net Cash Position Past Year | -491,000 |
| Long Term Debt Past Year | 20,251,000 |
| Long Term Debt Prior Year | 20,251,000 |
| Total Debt Most Recent Quarter | 20,420,000 |
| Equity to Debt Ratio Past Year | 0.68 |
| Equity to Debt Ratio Most Recent Quarter | 0.71 |
| Total Stockholder Equity Past Year | 43,211,000 |
| Total Stockholder Equity Prior Year | 33,569,000 |
| Total Stockholder Equity Most Recent Quarter | 49,903,000 |
Free Cash Flow |
|
| Free Cash Flow Twelve Trailing Months | -3,444,000 |
| Free Cash Flow Per Share Twelve Trailing Months | -0.04 |
| Free Cash Flow Past Year | 7,392,000 |
| Free Cash Flow Prior Year | -2,467,000 |
Options |
|
| Put/Call Ratio | 0.00 |
| Has Options | Options Chain |
| Liquidity Rating | |
Technical Analysis |
|
| Yahoo Finance Chart | Yahoo Finance Chart |
| MACD | 0.00 |
| MACD Signal | 0.00 |
| 20-Day Bollinger Lower Band | 0.00 |
| 20-Day Bollinger Middle Band | 0.00 |
| 20-Day Bollinger Upper Band | 0.00 |
| Beta | -0.13 |
| RSI | 0.00 |
| 50-Day SMA | 0.00 |
| 150-Day SMA | 0.00 |
| 200-Day SMA | 0.00 |
System |
|
| Modified | 10/7/2025 7:18:33 AM EST |